{
    "clinical_study": {
        "@rank": "114156", 
        "acronym": "STEEP", 
        "arm_group": [
            {
                "arm_group_label": "entecavir", 
                "arm_group_type": "Active Comparator", 
                "description": "standard drugs"
            }, 
            {
                "arm_group_label": "tenofovir", 
                "arm_group_type": "Active Comparator", 
                "description": "study drugs"
            }
        ], 
        "brief_summary": {
            "textblock": "Entecavir, a potent antiviral agent, has been widely used for treatment-na\u00efve chronic\n      hepatitis B patients. However,  about 20% of  patients showed  partial virologic response\n      after 2 year of entecavir therapy (33% in HBeAg positive, 10% in HBeAg negative patients).\n      Tenofovir  is a nucleotide analogue with more potent antiviral activity. In addition, there\n      is no cross resistance between the two drugs. Therefore it is assumed that tenofovir would\n      be effective in the treatment of chronic hepatitis B patients who shows partial virologic\n      response (detectable HBV DNA by real time PCR after 12 months of treatment) despite\n      treatment with entecavir.  In this study, we will compare the efficacy of switching to\n      tenofovir with continuing entecavir in patients who shows partial virologic response to\n      entecavir."
        }, 
        "brief_title": "Switching to Tenofovir Versus Continuing Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response During Entecavir Therapy: STEEP Study", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. CHB patients (positive HBsAg more than 6 months)\n\n          2. Age 19 years old\n\n          3. HBeAg positive or negative patients\n\n          4. Patients receiving entecavir 0.5 mg more than 12 months\n\n          5. Detectable HBV DNA by real time PCR (HBV > 60 IU/mL)\n\n          6. Compensated liver function (Child-Pugh-Turcotte score \u22647, prothrombin time 3 sec\n             above ULN or INR \u22641.5, serum albumin >3 g/dL, total bilirubin <2.5 mg/dL, no history\n             of variceal bleeding, diuretics or ascites requiring paracentesis, hepatic\n             encephalopathy)\n\n        Exclusion Criteria:\n\n          1. History of treatment with nucleotide analogue\n\n          2. Detectable entecavir resistant mutation by RFMP\n\n          3. Decompensated cirrhosis (CTP score >7)\n\n          4. Patients with HCC\n\n          5. Seropositivity to HCV, HDV or HIV\n\n          6. Pregnant and lactating woman"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711567", 
            "org_study_id": "STEEP study"
        }, 
        "intervention": [
            {
                "arm_group_label": "tenofovir", 
                "description": "tenofovir 300 mg qd", 
                "intervention_name": "tenofovir", 
                "intervention_type": "Drug", 
                "other_name": "tenofovir (viread)"
            }, 
            {
                "arm_group_label": "entecavir", 
                "description": "entecavir 0.5 mg qd", 
                "intervention_name": "entecavir", 
                "intervention_type": "Drug", 
                "other_name": "entecavir(baraclude) 0.5 mg qd"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tenofovir", 
                "Tenofovir disoproxil", 
                "Entecavir"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic Hepatitis B", 
            "TENOFOVIR", 
            "ENTECAVIR", 
            "PARTIAL RESPONDER"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": {
            "contact": {
                "email": "gudwns21@medimail.co.kr", 
                "last_name": "Hyung Joon Yim, M.D.", 
                "phone": "82-31-412-5583"
            }, 
            "contact_backup": {
                "email": "mothpickle@naver.com", 
                "last_name": "Sang Jun Suh, M.D.", 
                "phone": "82-31-412-4926"
            }, 
            "facility": {
                "address": {
                    "city": "Ansan", 
                    "country": "Korea, Republic of", 
                    "state": "Gyeonggi-do", 
                    "zip": "425-707"
                }, 
                "name": "Korea University Ansan Hospital"
            }, 
            "investigator": {
                "last_name": "Hyung Joon Yim, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "gudwns21@medimail.co.kr", 
            "last_name": "Hyung Joon Yim, M.D.", 
            "phone": "82-31-412-5583"
        }, 
        "overall_contact_backup": {
            "email": "mothpickle@naver.com", 
            "last_name": "Sang Jun Suh, M.D.", 
            "phone": "82-31-412-4926"
        }, 
        "overall_official": {
            "affiliation": "Korea University", 
            "last_name": "Hyung Joon Yim, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Virologic response rate at year 1 (12 months) (HBV DNA < 20 IU/mL)", 
            "safety_issue": "Yes", 
            "time_frame": "up to the end of year 1 (12 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711567"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Korea University", 
            "investigator_full_name": "Hyung Joon Yim", 
            "investigator_title": "Associate professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "-Degree of HBV DNA reduction, mean HBV DNA, biochemical and serologic response rates, resistance, and adverse events at year 1", 
            "safety_issue": "Yes", 
            "time_frame": "up to the end of year 1 (12 months)"
        }, 
        "source": "Korea University", 
        "sponsors": {
            "collaborator": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Korea University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}